Large enterprise deals are accelerating, prompting management to raise full-year 2026 guidance for the third time this year.

Aggressive reinvestment is expanding Vertiv's manufacturing scale while the company maintains high profitability, a balance ...

Owning its network infrastructure lets Bandwidth monetize AI-driven call volume without absorbing the computing costs rivals ...

A decade of aggressive buybacks has shrunk the share count by 37%, amplifying per-share earnings even as revenue growth ...

Microsoft ( MSFT -1.55%) posted results for the fiscal first quarter of 2027 (the three months ending Sept. 30, 2026) on ...

In its 2027 Long-Term Capital Market Assumptions report published in October 2026, J.P. Morgan projects that Bitcoin ( BTC +0 ...

Lee expects several catalysts to fuel that rally. As the largest developer-oriented blockchain for smart contracts and decentralized apps, Ethereum will grow as more stablecoins are minted and more ...

Lilly is the maker of tirzepatide, a drug sold under the name Mounjaro for type 2 diabetes and as Zepbound for weight loss.

The e-commerce company has beaten its own forecast all year. Is a cheaper stock enough to buy ahead of the next one?

Let's consider one company in each category. The one that could benefit from Anthropic's IPO is Broadcom ( AVGO -5.48%), and ...

The Schwab U.S. Dividend Equity ETF has a current yield of 3.1%. To generate the equivalent of $1,000 per month in dividend ...

The only real exceptions to the "claims up, stocks down" rule is the late 1980s, when initial jobless claims started moving ...